Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team
January 04, 2021 16:30 ET
|
Checkmate Pharmaceuticals Inc.
Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI)...
Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
December 08, 2020 07:00 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its...
Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress
November 13, 2020 07:00 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
Checkmate Pharmaceuticals Presents Updated Clinical Data with CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
November 09, 2020 09:00 ET
|
Checkmate Pharmaceuticals Inc.
CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial Encouraging new data on pathological responses and 1-year RFS...
Checkmate Pharmaceuticals to Present at the Upcoming Jefferies Virtual London Healthcare Conference
November 03, 2020 07:00 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology...
Checkmate Pharmaceuticals Announces Data Presentations for CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
October 15, 2020 09:20 ET
|
Checkmate Pharmaceuticals Inc.
CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma Encouraging new data on pathological responses and 1-year RFS with neoadjuvant...
Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress
September 18, 2020 07:00 ET
|
Checkmate Pharmaceuticals Inc.
Successfully completed IPO in August 2020 raising $76.6 million in gross proceedsOn track to initiate planned new clinical trials in melanoma and head and neck cancer CAMBRIDGE, Mass., Sept. 18,...
Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering
August 06, 2020 21:17 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the...